Panagora Asset Management Inc. Trims Stake in Zoetis Inc. $ZTS

Panagora Asset Management Inc. lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 51.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,428 shares of the company’s stock after selling 8,834 shares during the period. Panagora Asset Management Inc.’s holdings in Zoetis were worth $1,314,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Savvy Advisors Inc. raised its holdings in Zoetis by 54.0% in the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after purchasing an additional 1,114 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after buying an additional 152 shares in the last quarter. Canoe Financial LP grew its position in shares of Zoetis by 859.0% in the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after buying an additional 11,975 shares during the period. Strs Ohio bought a new position in shares of Zoetis in the 1st quarter worth about $22,891,000. Finally, Chicago Partners Investment Group LLC increased its stake in shares of Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after acquiring an additional 1,961 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $120.33 on Friday. The firm has a fifty day simple moving average of $134.27 and a two-hundred day simple moving average of $148.09. The firm has a market cap of $53.03 billion, a PE ratio of 20.26, a P/E/G ratio of 2.54 and a beta of 0.97. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $181.85. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. The business’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date was Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Wednesday. Morgan Stanley dropped their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, KeyCorp initiated coverage on Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.